McKesson (MCK) Q3 FY26 earnings call: guidance and Q&A

Can you elaborate on specific technology investments driving productivity in annual verification season and the long-term margin opportunity for the Prescription Technology Solutions segment?

Management highlighted investments in AI and automation to streamline workflows, such as automating emails and building digitally native tools for new regulatory requirements like DSCSA, which autonomously resolves 75% of inquiries. They noted that half of RxTS revenue comes from technology services supporting biopharma, and positioning the portfolio to automate these services will continue to improve margin trajectory, which has already seen 130 bps growth YoY.

“we look to position the portfolio to continue to automate capabilities and automated services and products on behalf of our biopharma partners. And I think we like the trajectory that we're seeing in the business. If you look at the segment, we've seen operating margins grow over 130 basis points year-over-year.”

asked by Allen Lutz · answered by Britt Vitalone

What are the key puts and takes for FY27 guidance, and what's driving the sequential margin dynamics in the Oncology & Multispecialty segment?

Management will provide FY27 guidance in May. For Oncology & Multispecialty, they noted strong specialty distribution growth, provider acquisitions (PRISM, Core Ventures), and operational efficiencies as positive building blocks. While quarter-to-quarter mix can cause variability, organic operating profit grew 15% excluding acquisitions, and the overall trajectory is positive, with acquisitions being accretive to margins over time.

“we had 24% organic revenue growth. When you strip away the acquisitions, we had 15% organic adjusted operating profit growth. Quarter-to-quarter, you're going to have some variability from mix. Generally speaking, we're pleased with the -- how the segment is building and progressing on both revenue, operating profit dollars and the overall margins and adding acquisitions like PRISM and Core Ventures are going to be accretive to all of those.”

asked by Brian Tanquil · answered by Britt Vitalone

Following up on the previous question, what specific factors are driving the quarter-over-quarter margin improvement in Oncology & Multispecialty, considering the prior quarter's non-recurring gain?

Britt clarified that adding providers to the Florida Cancer and Vision platforms, along with continued growth in specialty and oncology products, are positively impacting segment operating margins. He also noted that early automation and AI capabilities are having an impact, which is expected to build over time, and that PRISM and Florida Cancer acquisitions are accretive to margins.

“As we added the providers to the platform for Florida Cancer, as we've continued to build out our vision platform, those are positive mix attributes to the segment. We're also seeing continued growth in specialty and specifically in oncology products. So those are favorably impacting the overall operating margins of the segment.”

asked by Lisa Gill · answered by Britt Vitalone

The implied Q4 guidance for North American Pharma suggests acceleration. What are the drivers, and how should we interpret the wider-than-normal range?

Britt clarified that the width of the operating profit guidance range for North American Pharma is the same, but the range itself was increased from 5%-9% to 8%-12%. He attributed this to strong Q3 performance, robust specialty distribution growth, operational excellence, and stable utilization trends. He emphasized that the momentum, mix, and scale of operations are performing well.

“We took our adjusted operating profit growth targets for the full year from 5% to 9% to 8% to 12%. So the width of the range is the same. What we've done is just simply increased it. One, for the performance that we've seen through the first 3 quarters of the year; and two, really, the confidence that we have in the trajectory through the balance of the year, given really the strong specialty distribution growth that we're seeing, our continued focus and execution on operational excellence, the utilization trends that we're seeing.”

asked by Michael Cherny · answered by Britt Vitalone

How is McKesson navigating the dynamic regulatory environment, including IRA and MFN, and influencing policy discussions?

Brian stated that IRA Part D's first 10 drugs are in line with expectations and McKesson has constructive conversations with manufacturers. For MFN, he believes it's largely a niche population and McKesson has assets to support if the market shifts. He views the overall policy landscape as navigable, citing that Globe (Part B) implications are not material due to exemptions and direct manufacturer-to-Medicare rebates. McKesson engages with policymakers to find solutions that support community-based care.

“As we have evaluated it, we continue to think that implications for McKesson are quite navigable. If you take something like Globe, which is Part B, it's a -- it exempts anyone that already has an IRA drug out there. It is only applicable to 25% of the ZIP codes. It's only about 35% of oncology Medicare business. And as you start to do the math and chunk it down, we don't think it's going to be that material.”

asked by Eric Percher · answered by Brian Tyler

Given the increased North American Pharma operating profit guidance, are there any positive or negative trends heading into Q4 and FY27 that we should be aware of, especially considering market concerns about potential deceleration?

Britt reiterated that the North American Pharma operating profit guidance range was raised, not widened, reflecting strong Q3 performance and confidence in the business trajectory. He highlighted strong specialty distribution growth, operational excellence, and stable utilization trends as positive drivers. He emphasized that the company is very pleased with its performance and the trends observed, including growth in retail pharmacy and health systems.

“We took our adjusted operating profit growth targets for the full year from 5% to 9% to 8% to 12%. So the width of the range is the same. What we've done is just simply increased it. One, for the performance that we've seen through the first 3 quarters of the year; and two, really, the confidence that we have in the trajectory through the balance of the year, given really the strong specialty distribution growth that we're seeing, our continued focus and execution on operational excellence, the utilization trends that we're seeing.”

asked by Glen Santangelo · answered by Britt Vitalone

Given the IT investments, should we expect a shift towards internal growth investments over acquisitions, or a continuation of the historical pattern?

Brian stated that the philosophy hasn't changed. McKesson continuously invests in its businesses for new products and differentiation, and also acquires capabilities when it's more efficient than building internally. The capital allocation framework remains the same: prioritize internal growth investments (people, technology) and pursue inorganic acquisitions aligned with strategy and financial returns. He believes they have a successful track record of both.

“Our first priority is always to invest back in the growth of the business, and that can take two forms. That could be internally, we can invest in people, technologies, other resources to help expand the differentiation and expand maybe our market opportunities or we can do it through inorganically. And we're -- I think we've got a successful track record of doing both, and we would look to continue that.”

asked by Elizabeth Anderson · answered by Brian Tyler

McKesson is seeing accelerating core growth while competitors are decelerating. What specific factors are contributing to McKesson's differentiated performance?

Brian attributed McKesson's performance to a clear, long-standing strategy, a focused management team investing in and deploying capital to advance those strategies, successful capital deployment through acquisitions like PRISM Vision and Florida Cancer, and strong day-to-day execution by teams across the business. He emphasized a mindset of continuous improvement and embracing possibilities.

“I think it boils down to a clear strategy that's been in place for an extended period of time, a focused management team that is investing and deploying capital and resources to advance those strategies. Some good deployment of capital this past year, both PRISM Vision and Florida Cancer were great additions that fit right into our model that we're very, very pleased about.”

asked by Charles Rhyee · answered by Brian Tyler

Can you provide more color on the positive trends in annual verifications and whether GLP-1s are introducing new prior authorization utilizers, contributing to confidence in RxTS growth?

Brian noted it's very early days for oral GLP-1 launches, making it hard to dissect trends, but they are seeing some prior authorizations. He expects the GLP-1 category to continue to grow, but the share of oral vs. injectable or net new customers is uncertain. Britt added that annual verification programs are off to a good start with meaningful volume growth, and new brands and programs are also contributing positively to RxTS.

“it's very early days for the oral GLP-1 launch. So it's really hard to try to dissect trends from the -- given the size of the injectable market versus a few weeks of launch of the oral drug. But we are seeing some prior authorizations come through there.”

asked by Kevin Caliendo · answered by Brian Tyler

With anticipated brand drug price decreases in Q4, how has McKesson maintained its value proposition and economics, and what has been the impact of pricing actions?

Britt stated that McKesson maintains strong relationships with manufacturing partners and has constructive conversations about fair value for services. Pricing activity and changes have been in line with expectations, not materially impacting economics from a bottom-line perspective, though pricing declines will affect revenue. He emphasized the ability to retain value despite market changes.

“what we've seen thus far in terms of pricing activity and changes in prices has been right in line with our expectations, it's really nothing out of line and really consistent with what we've seen over the past few years. So there has been a lot of a lot of changes over the last several months, but nothing that has impacted our economics, at least from a bottom line perspective.”

asked by George Hill · answered by Britt Vitalone